Photobiomodulation , Exosome Therapy , Functional Medicine , Stemcell therapy
Friday, April 14th, 2023, 13:00 to 14:30 Germany Time
Dear Dr,
Welcome to the European LASER Academy world webinar, Regenerative Medicine in Clinic,
· Photobiomodulation
· Exosome Therapy
· Functional Medicine
· Stemcell therapy
Friday, April 14th, 2023, 13:00 to 14:30 Germany Time
Please leave your cell phone number including full zone code such as +49 17 22 33 22 81.
We will send you a message as a reminder one day earlier.
We will send you a link of the webinar on April 12th, 2023.
Please feel free for any questions.
Best wishes
SEMINAR CUM WORKSHOP ON INTRODUCTION TO LASER THERAPY
26th SEPT 2022 , 10 AM to 4:30 PM
ABOUT: LASER TH ERAPY (PHOTODYNAM TH ERAPY) Laser therapy is an integrative medical treatment method to support the body's own physiological regeneration processes. Laser therapy can be used in treating back pain, joint pain, cancer, osteoarthritis, atopic dermatitis, wound healing disorders, diabetic ulcers, hypertrophic scars, rosacea and acne etc. This compact Seminar will cover the basic knowledge of medical laser therapy and a range of important therapeutic concepts for Laser Acupuncture and Photo-BioModulation (PBM). The participants will benefit from the more than 30 years of clinical experience of Dr. Weber and the European Laser clinics. Laser Acupuncture offers therapist many new opportunities and therapeutic possibilities, especially in children and adults with needle phobias. The curative application of light is known for centuries. Laser therapy is a consistent adva ncement of this tradition: Light can heal. Laser Acupuncture is one of the terrific options of therapeutic effects of light. All known acupuncture points can be treated using laser effectively.
Stem cell therapy in amyotrophic lateral sclerosis: a methodological approach in humans
Abstract
INTRODUCTION: Recently it has been shown in animal models of amyotrophic lateral sclerosis (ALS) that stem cells significantly slow the progression of the disease and prolong survival. We have evaluated the feasibility and safety of a method of intraspinal cord implantation of autologous mesenchymal stem cells (MSCs) in a few well‐monitored patients with ALS.
METHOD:
INTRODUCTION: Recently it has been shown in animal models of amyotrophic lateral sclerosis (ALS) that stem cells significantly slow the progression of the disease and prolong survival. We have evaluated the feasibility and safety of a method of intraspinal cord implantation of autologous mesenchymal stem cells (MSCs) in a few well‐monitored patients with ALS.
METHOD:
Bone marrow collection was performed according to the standard procedure by aspiration from the posterior iliac crest. Ex vivo expansion of mesenchymal stem cells was induced according to Pittenger’s protocol. The cells were suspended in 2 ml of autologous cerebrospinal fluid and transplanted into the spinal cord by a micrometric pump injector.
RESULTS:
RESULTS:
No patient manifested major adverse events such as respiratory failure or death. Minor adverse events were intercostal pain irradiation (4 patients) which was reversible after a mean period of three days after surgery, and leg sensory dysesthesia (5 patients) which was reversible after a mean period of six weeks after surgery. No modification of the spinal cord volume or other signs of abnormal cell proliferation were observed.
CONCLUSIONS: Our results appear to demonstrate that the procedures of ex vivo expansion of autologous mesenchymal stem cells and of transplantation into the spinal cord of humans are safe and well tolerated by ALS patients.
CONCLUSIONS: Our results appear to demonstrate that the procedures of ex vivo expansion of autologous mesenchymal stem cells and of transplantation into the spinal cord of humans are safe and well tolerated by ALS patients.
more information
Stem cell therapy in amyotrophic lateral sclerosis: a methodological approach in humans
Abstract
INTRODUCTION: Recently it has been shown in animal models of amyotrophic lateral sclerosis (ALS) that stem cells significantly slow the progression of the disease and prolong survival. We have evaluated the feasibility and safety of a method of intraspinal cord implantation of autologous mesenchymal stem cells (MSCs) in a few well‐monitored patients with ALS.
METHOD:
INTRODUCTION: Recently it has been shown in animal models of amyotrophic lateral sclerosis (ALS) that stem cells significantly slow the progression of the disease and prolong survival. We have evaluated the feasibility and safety of a method of intraspinal cord implantation of autologous mesenchymal stem cells (MSCs) in a few well‐monitored patients with ALS.
METHOD:
Bone marrow collection was performed according to the standard procedure by aspiration from the posterior iliac crest. Ex vivo expansion of mesenchymal stem cells was induced according to Pittenger’s protocol. The cells were suspended in 2 ml of autologous cerebrospinal fluid and transplanted into the spinal cord by a micrometric pump injector.
RESULTS:
RESULTS:
No patient manifested major adverse events such as respiratory failure or death. Minor adverse events were intercostal pain irradiation (4 patients) which was reversible after a mean period of three days after surgery, and leg sensory dysesthesia (5 patients) which was reversible after a mean period of six weeks after surgery. No modification of the spinal cord volume or other signs of abnormal cell proliferation were observed.
CONCLUSIONS: Our results appear to demonstrate that the procedures of ex vivo expansion of autologous mesenchymal stem cells and of transplantation into the spinal cord of humans are safe and well tolerated by ALS patients.
CONCLUSIONS: Our results appear to demonstrate that the procedures of ex vivo expansion of autologous mesenchymal stem cells and of transplantation into the spinal cord of humans are safe and well tolerated by ALS patients.
more information
Einführungs- Und Vertiefungs – Seminar15. – 17. Oktober, 2021 In Frankfurt
GRUNDLAGEN DER LLLT / PBM UND LASER-AKUPUNKTUR
SEMINAR CUM WORKSHOP ON INTRODUCTION TO LASER THERAPY
26th SEPT 2022 , 10 AM to 4:30 PM